文献速递新发突发、热带与寄生虫病

RH5.1/Matrix-M血期疟疾疫苗在布基纳法索儿童中的安全性和有效性:双盲、随机、对照2b期试验的中期结果

Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
PubMed 文献 · Lancet Infect Dis · 2024-12-10

该双盲随机对照2b期试验在布基纳法索纳诺罗纳入361名5-17月龄儿童,比较RH5.1/Matrix-M与狂犬病对照疫苗。延迟第三剂方案疫苗有效性为55%(95%CI 20-75%;p=0.0071),每月方案为40%(95%CI -3-65%;p=0.066)。疫苗安全性良好,未报告严重不良事件。

要点

  • 延迟第三剂方案疫苗有效性55%(95%CI 20-75%;p=0.0071)。
  • 每月方案疫苗有效性40%(95%CI -3-65%;p=0.066)。
  • 局部肿胀和发热最常见,未报告严重不良事件。

核心结论

  • RH5.1/Matrix-M在非洲儿童中似乎安全且高度免疫原性,延迟第三剂方案对临床疟疾显示出有前景的有效性。
  • 该试验正在进行中以进一步监测随时间推移的有效性。

研究设计与样本

  • 双盲、随机、对照、2b期试验,在布基纳法索纳诺罗的季节性疟疾传播地区进行。
  • 共筛查412名5-17月龄儿童,排除51名,纳入361名。
  • 第一队列:RH5.1/Matrix-M延迟第三剂组119名,狂犬病对照疫苗组62名;第二队列:RH5.1/Matrix-M每月组120名,狂犬病对照疫苗组60名。
  • 儿童在每个队列内按2:1随机分配接受RH5.1/Matrix-M或Rabivax-S,使用独立统计师生成的区组随机化分配列表。
  • 受试者、其家庭和研究团队对分组分配设盲,仅准备疫苗的药剂师非盲。

主要发现

  • 两个队列中RH5.1/Matrix-M均具有良好安全性特征且耐受性良好,大多数不良事件为轻度,最常见为局部肿胀和发热,未报告严重不良事件。
  • 延迟第三剂方案与合并对照组比较,疫苗有效性为55%(95%CI 20-75%;p=0.0071)。
  • 每月方案与合并对照组比较,疫苗有效性为40%(95%CI -3-65%;p=0.066)。
  • 两个队列中接种RH5.1/Matrix-M的参与者在第三剂后14天均显示高浓度抗RH5.1血清IgG抗体,纯化IgG对恶性疟原虫显示高水平体外生长抑制活性。
  • 接受延迟第三剂方案的参与者生长抑制活性为79.0%(SD 14.3),每月方案为74.2%(SD 15.9),延迟第三剂方案较高(p=0.016)。

关键数值与推荐

  • 共同主要结局:一是RH5.1/Matrix-M的安全性和反应原性;二是第三剂后14天至6个月期间(符合方案样本)对临床疟疾的保护效力(以首次临床疟疾发作时间衡量,使用Cox回归模型)。
  • 第一队列接种延迟第三剂方案(0、1、5月)或等效狂犬病对照疫苗;第二队列接种0、1、2月方案或等效狂犬病对照疫苗。
  • 每次接种10 μg RH5.1蛋白加50 μg Matrix-M佐剂,肌内注射,共三剂。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two pre-erythrocytic vaccines (R21/Matrix-M and RTS,S/AS01) are now approved for Plasmodium falciparum malaria. However, neither induces blood-stage immunity against parasites that break through from the liver. RH5.1/Matrix-M, a blood-stage P falciparum malaria vaccine candidate, was highly immunogenic in Tanzanian adults and children. We therefore assessed the safety and efficacy of RH5.1/Matrix-M in Burkinabe children. METHODS: In this double-blind, randomised, controlled, phase 2b trial, RH5.1/Matrix-M was given to children aged 5-17 months in Nanoro, Burkina Faso, a seasonal malaria transmission setting. Children received either three intramuscular vaccinations with 10 μg RH5.1 protein with 50 μg Matrix-M adjuvant or three doses of rabies control vaccine, Rabivax-S, given either in a delayed third-dose (0, 1, and 5 month) regimen (first cohort) or a 0, 1, and 2 month regimen (second cohort). Vaccinations were completed part way through the malaria season. Children were randomly assigned 2:1 within each cohort to receive RH5.1/Matrix-M or Rabivax-S. Participants were assigned according to a random allocation list generated by an independent statistician using block randomisation with variable block sizes. Participants, their families, and the study teams were masked to group allocation; only pharmacists who prepared the vaccines were unmasked. Vaccine safety, immunogenicity, and efficacy were evaluated. The coprimary outcomes assessed were: first, the safety and reactogenicity of RH5.1/Matrix-M; and second, the protective efficacy of RH5.1/Matrix-M against clinical malaria (measured as time to first episode of clinical malaria, using a Cox regression model) from 14 days to 6 months after the third vaccination in the per-protocol sample. This ongoing trial is registered with ClinicalTrials.gov (NCT05790889). FINDINGS: From April 6 to 13 and July 3 to 7, 2023, 412 children aged 5-17 months were screened, and 51 were excluded. A total of 361 children were enrolled in this study. In the first cohort, 119 were assigned to the RH5.1/Matrix-M delayed third-dose group, and 62 to the equivalent rabies control group. The second cohort included 120 children in the monthly RH5.1/Matrix-M group and 60 in the equivalent rabies control group. The final vaccination was administered to all groups from Sept 4 to 21, 2023. RH5.1/Matrix-M in both cohorts had a favourable safety profile and was well tolerated. Most adverse events were mild, with the most common being local swelling and fever. No serious adverse events were reported. Comparing the RH5.1/Matrix-M delayed third-dose regimen with the pooled control groups resulted in a vaccine efficacy of 55% (95% CI 20 to 75%; p=0·0071). The same analysis showed a vaccine efficacy of 40% (-3 to 65%; p=0·066) when comparing the monthly regimen with the pooled control groups. Participants vaccinated with RH5.1/Matrix-M in both cohorts showed high concentrations of anti-RH5.1 serum IgG antibodies 14 days after the third vaccination, and the purified IgG showed high levels of in vitro growth inhibition activity against P falciparum; these responses were higher in patients who received the RH5.1/Matrix-M vaccine delayed third-dose regimen, as opposed to monthly regimen (growth inhibition activity 79·0% [SD 14·3] vs 74·2% [SD 15·9]; p=0·016). INTERPRETATION: RH5.1/Matrix-M appears safe and highly immunogenic in African children and shows promising efficacy against clinical malaria when given in a delayed third-dose regimen. This trial is ongoing to further monitor efficacy over time. FUNDING: The European and Developing Countries Clinical Trials Partnership, the UK Medical Research Council, the National Institute for Health and Care Research Oxford Biomedical Research Centre, the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, the US Agency for International Development, and the Wellcome Trust.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Natama HM, Salkeld J, Somé A, et al. Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children. Lancet Infect Dis. 2024. PMID: 39672183. doi:10.1016/S1473-3099(24)00752-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。